Geretti et al. [55] investigated a strategy to improve the efficacy of HER2-targeted PEGylated liposomal doxorubicin (PGL/MM-302) in HER2-positive breast cancer by combining it with a tumor-priming dose of cyclophosphamide (CPA). Here, ERBB2 is linked to neoplasm.